Advertisement

Archives of Toxicology

, Volume 93, Issue 7, pp 2007–2019 | Cite as

Role of microglial activation and neuroinflammation in neurotoxicity of acrylamide in vivo and in vitro

  • Cai Zong
  • Rieka Hasegawa
  • Makoto Urushitani
  • Lingyi Zhang
  • Daichi Nagashima
  • Toshihiro Sakurai
  • Sahoko Ichihara
  • Seiichiroh Ohsako
  • Gaku IchiharaEmail author
Organ Toxicity and Mechanisms

Abstract

Acrylamide, a soft electrophile, is widely used in the industry and laboratories, and also contaminates certain foods. Neurotoxicity and neurodegenerative effects of acrylamide have been reported in humans and experimental animals, although the underlying mechanism remains obscure. Activation of microglia and neuroinflammation has been demonstrated in various neurodegenerative diseases as well as other pathologies of the brain. The present study aimed to investigate the role of microglial activation and neuroinflammation in acrylamide neurotoxicity. Male 10-week-old Wistar rats were exposed to acrylamide by gavage at 0, 0.2, 2, or 20 mg/kg BW, once per day for 5 weeks. The results showed that 5-week exposure to acrylamide induced inflammatory responses in the cerebral cortex, evident by upregulated mRNA and protein expression of pro-inflammatory cytokines IL-1β, IL-6, and IL-18. Acrylamide also induced activation of microglia, indicated by increased expression of microglial markers, CD11b and CD40, and increased CD11b/c-positive microglial area and microglial process length. In vitro studies using BV-2 microglial cells confirmed microglial inflammatory response, as evident by time- (0–36 h; 50 μM) and dose- (0–500 μM; 24 h) dependent increase in mRNA expression of IL-1β and IL-18, as well as the inflammatory marker iNOS. Furthermore, acrylamide-induced upregulation of pro-inflammatory cytokines was mediated through the NLRP3 inflammasome pathway, as evident by increased expression of NLRP3, caspase 1, and ASC in the rat cerebral cortex, and by the inhibitory effects of NLRP3 inflammasome inhibitor on the acrylamide-induced upregulation of NLRP3, caspase 1, IL-1β, and IL-18 in BV-2 microglia.

Keywords

Acrylamide Electrophile Microglia Neuroinflammation NLRP3 inflammasome 

Notes

Acknowledgements

This work was supported by Grants-in-Aid for Scientific Research on Innovative Areas (#17H06396) and for Scientific Research (B) (#16H02965), Japan Society for the Promotion of Science. The authors would like to thank Ms. Satoko Arai for the excellent secretarial supports.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Supplementary material

204_2019_2471_MOESM1_ESM.docx (23 kb)
Supplementary material 1 (DOCX 22 kb)

References

  1. Abramsson-Zetterberg L, Wong J, Ilbäck NG (2005) Acrylamide tissue distribution and genotoxic effects in a common viral infection in mice. Toxicology 211:70–76CrossRefGoogle Scholar
  2. Allan SM, Rothwell NJ (2001) Cytokines and acute neurodegeneration. Nat Rev Neurosci 2:734–744CrossRefGoogle Scholar
  3. ATSDR (Agency for Toxic Substances and Disease Registry) (2012) Toxicological profile for acrylamide. U.S. Department of Health and Human Services. Public Health Service. https://www.atsdr.cdc.gov/toxprofiles/tp203.pdf. Accessed 9 May 2019
  4. Basu A, Krady JK, Levison SW (2004) Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res 78:151–156CrossRefGoogle Scholar
  5. Block ML, Hong JS (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76:77–98CrossRefGoogle Scholar
  6. Block ML, Hong JS (2007) Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35:1127–1132CrossRefGoogle Scholar
  7. Blum-Degen D, Müller T, Kuhn W et al (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202:17–20CrossRefGoogle Scholar
  8. Brown GC, Neher JJ (2010) Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 41:242–247CrossRefGoogle Scholar
  9. Campbell IL (2005) Cytokine-mediated inflammation, tumorigenesis, and disease-associated JAK/STAT/SOCS signaling circuits in the CNS. Brain Res Rev 48:166–177CrossRefGoogle Scholar
  10. Campbell IL, Abraham CR, Masliah E et al (1993) Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci 90:10061–10065CrossRefGoogle Scholar
  11. Chen JH, Chou CC (2015) Acrylamide inhibits cellular differentiation of human neuroblastoma and glioblastoma cells. Food Chem Toxicol 82:27–35CrossRefGoogle Scholar
  12. Chen K, Huang J, Gong W et al (2006) CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system. Cell Mol Immunol 3:163–169Google Scholar
  13. Coll RC, Robertson AAB, Chae JJ et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21:248–255CrossRefGoogle Scholar
  14. Deng H, He F, Zhang S et al (1993) Quantitative measurements of vibration threshold in healthy adults and acrylamide workers. Int Arch Occup Environ Health 65:53–56CrossRefGoogle Scholar
  15. Doerge DR, Young JF, McDaniel LP, Twaddle NC, Churchwell MI (2005) Toxicokinetics of acrylamide and glycidamide in Fischer 344 rats. Toxicol Appl Pharm 208:199–209CrossRefGoogle Scholar
  16. Erkekoglu P, Baydar T (2014) Acrylamide neurotoxicity. Nutr Neurosci 17:49–57CrossRefGoogle Scholar
  17. Felderhoff-Mueser U, Sifringer M, Polley O et al (2005) Caspase-1-processed interleukins in hyperoxia-induced cell death in the developing brain. Ann Neurol 57:50–59CrossRefGoogle Scholar
  18. Freeman LC, Ting JPY (2016) The pathogenic role of the inflammasome in neurodegenerative diseases. J Neurochem 136:29–38CrossRefGoogle Scholar
  19. Garland TO, Patterson MWH (1967) Six cases of acrylamide poisoning. BMJ 4:134–138CrossRefGoogle Scholar
  20. Glass CK, Saijo K, Winner B et al (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140:918–934CrossRefGoogle Scholar
  21. Griffin WS, Stanley LC, Ling C et al (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86:7611–7615CrossRefGoogle Scholar
  22. He FS, Zhang SL, Wang HL et al (1989) Neurological and electroneuromyographic assessment of the adverse effects of acrylamide on occupationally exposed workers. Scand J Work Environ Health 15:125–129CrossRefGoogle Scholar
  23. Heneka MT, McManus RM, Latz E (2018) Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci 19:610–621CrossRefGoogle Scholar
  24. Henn A, Lund S, Hedtjärn M et al (2009) The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. Altex 26:83–94CrossRefGoogle Scholar
  25. Hennig P, Garstkiewicz M, Grossi S et al (2018) The crosstalk between Nrf2 and inflammasomes. Int J Mol Sci 19:1–19CrossRefGoogle Scholar
  26. Jin X, Yamashita T (2016) Microglia in central nervous system repair after injury. J Biochem 159:491–496CrossRefGoogle Scholar
  27. Kraft AD, Harry GJ (2011) Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health 8:2980–3018CrossRefGoogle Scholar
  28. Kumagai Y, Abiko Y (2017) Environmental electrophiles: protein adducts, modulation of redox signaling, and interaction with persulfides/polysulfides. Chem Res Toxicol 30:203–219CrossRefGoogle Scholar
  29. Lawson LJ, Perry VH, Dri P, Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39:151–170CrossRefGoogle Scholar
  30. Li S, Cui N, Zhang C et al (2006) Effect of subchronic exposure to acrylamide induced on the expression of bcl-2, bax and caspase-3 in the rat nervous system. Toxicology 217:46–53CrossRefGoogle Scholar
  31. LoPachin RM (2004) The changing view of acrylamide neurotoxicity. Neurotoxicology 25:617–630CrossRefGoogle Scholar
  32. LoPachin RM, Barber DS (2006) Synaptic cysteine sulfhydryl groups as targets of electrophilic neurotoxicants. Toxicol Sci 94:240–255CrossRefGoogle Scholar
  33. LoPachin RM, Gavin T (2008) Acrylamide-induced nerve terminal damage: relevance to neurotoxic and neurodegenerative mechanisms. J Agric Food Chem 56:5994–6003CrossRefGoogle Scholar
  34. LoPachin RM, Gavin T (2012) Molecular mechanism of acrylamide neurotoxicity: lessons learned from organic chemistry. Environ Health Perspect 120:1650–1657CrossRefGoogle Scholar
  35. LoPachin RM, Ross JF, Reid ML et al (2002) Neurological evaluation of toxic axonopathies in rats: acrylamide and 2,5-hexanedione. Neurotoxicology 23:95–110CrossRefGoogle Scholar
  36. LoPachin RM, Gavin T, Decaprio A, Barber DS (2012) Application of the hard and soft, acids and bases (HSAB) theory to toxicant–target interactions. Chem Res Toxicol 25:239–251CrossRefGoogle Scholar
  37. Marlowe C, Clark MJ, Mast RW et al (1986) The distribution of [14C]acrylamide in male and pregnant Swiss-Webster mice studied by whole-body autoradiography. Toxicol Appl Pharmacol 86:457–465CrossRefGoogle Scholar
  38. Na KS, Jung HY, Kim YK (2014) The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 48:277–286CrossRefGoogle Scholar
  39. O’Sullivan JB, Ryan KM, Curtin NM et al (2009) Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int J Neuropsychopharmacol 12:687–699CrossRefGoogle Scholar
  40. Oono M, Okado-Matsumoto A, Shodai A et al (2014) Transglutaminase 2 accelerates neuroinflammation in amyotrophic lateral sclerosis through interaction with misfolded superoxide dismutase 1. J Neurochem 128:403–418CrossRefGoogle Scholar
  41. Owens T, Babcock AA, Millward JM, Toft-Hansen H (2005) Cytokine and chemokine inter-regulation in the inflamed or injured CNS. Brain Res Rev 48:178–184CrossRefGoogle Scholar
  42. Pennisi M, Malaguarnera G, Puglisi V et al (2013) Neurotoxicity of acrylamide in exposed workers. Int J Environ Res Public Health 10:3843–3854CrossRefGoogle Scholar
  43. Perry VH, Teeling J (2013) Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol 35:601–612CrossRefGoogle Scholar
  44. Ramsey JC, Young JD, Gorzinsky SJ (1984) Acrylamide: toxicodynamics in rats. Submitted to the US Environmental Protection Agency under TSCA Section 4. OTS0507270. [Unpublished study for peer review]Google Scholar
  45. Reinoso RF, Telfer BA, Rowland M (1997) Tissue water content in rats measured by desiccation. J Pharm Toxicol Methods 38:87–92CrossRefGoogle Scholar
  46. Rotshenker S (2003) Microglia and macrophage activation and the regulation of complement-receptor-3 (CR46/MAC-1)-mediated myelin phagocytosis in injury and disease. J Mol Neurosci 21:65–72CrossRefGoogle Scholar
  47. Schroder K, Tschopp J (2010) The inflammasomes. Cell 140:821–832CrossRefGoogle Scholar
  48. Song L, Pei L, Yao S et al (2017) NLRP3 inflammasome in neurological diseases, from functions to therapies. Front Cell Neurosci 11:1–17Google Scholar
  49. Stansley B, Post J, Hensley K (2012) A comparative review of cell culture systems for the study of microglial biology in Alzheimer’s disease. J Neuroinflamm 9:577CrossRefGoogle Scholar
  50. Stow JL, Murray RZ (2013) Intracellular trafficking and secretion of inflammatory cytokines. Cytokine Growth Factor Rev 24:227–239CrossRefGoogle Scholar
  51. Streit WJ, Mrak RE, Griffin WST (2004) Microglia and neuroinflammation: a pathological perspective. J Neuroinflamm 1:1–4CrossRefGoogle Scholar
  52. Subramanian K, Mohideen SS, Suzumura A et al (2012) Exposure to 1-bromopropane induces microglial changes and oxidative stress in the rat cerebellum. Toxicology 302:18–24CrossRefGoogle Scholar
  53. Tareke E, Rydberg P, Karlsson P et al (2000) Acrylamide: a cooking carcinogen? Chem Res Toxicol 13:517–522CrossRefGoogle Scholar
  54. Tareke E, Rydberg P, Karlsson P et al (2002) Analysis of acrylamide, a carcinogen formed in heated foodstuffs. J Agric Food Chem 50:4998–5006CrossRefGoogle Scholar
  55. Urban M, Kavvadias D, Riedel K et al (2006) Urinary mercapturic acids and a hemoglobin adduct for the dosimetry of acrylamide exposure in smokers and nonsmokers. Inhal Toxicol 18:831–839CrossRefGoogle Scholar
  56. Van Everbroeck B, Dewulf E, Pals P et al (2002) The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt–Jakob disease. Neurobiol Aging 23:59–64CrossRefGoogle Scholar
  57. Virk-Baker MK, Nagy TR, Barnes S, Groopman J (2014) Dietary acrylamide and human cancer: a systematic review of literature. Nutr Cancer 66:774–790CrossRefGoogle Scholar
  58. Wang W, Tan M, Yu J, Tan L (2015) Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann Transl Med 3:1–15Google Scholar
  59. Yang TT, Lin C, Hsu CT et al (2013) Differential distribution and activation of microglia in the brain of male C57BL/6J mice. Brain Struct Funct 218:1051–1060CrossRefGoogle Scholar
  60. Zhang L, Geohagen BC, Gavin T, LoPachin RM (2016) Joint toxic effects of the type-2 alkene electrophiles. Chem Biol Interact 254:198–206CrossRefGoogle Scholar
  61. Zhao M, Lewis Wang FS, Hu X et al (2017) Acrylamide-induced neurotoxicity in primary astrocytes and microglia: roles of the Nrf2-ARE and NF-κB pathways. Food Chem Toxicol 106:25–35CrossRefGoogle Scholar
  62. Zhou K, Shi L, Wang Y et al (2016) Recent advances of the nLRP3 inflammasome in central nervous system disorders. J Immunol Res 2016:1–9Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Cai Zong
    • 1
  • Rieka Hasegawa
    • 1
  • Makoto Urushitani
    • 2
  • Lingyi Zhang
    • 1
  • Daichi Nagashima
    • 1
    • 3
  • Toshihiro Sakurai
    • 1
  • Sahoko Ichihara
    • 4
  • Seiichiroh Ohsako
    • 5
  • Gaku Ichihara
    • 1
    Email author
  1. 1.Department of Occupational and Environmental Health, Graduate School of Pharmaceutical SciencesTokyo University of ScienceChibaJapan
  2. 2.Department of NeurologyShiga University of Medical ScienceShigaJapan
  3. 3.Department of Hygiene, Public Health, and Preventive MedicineShowa University School of MedicineTokyoJapan
  4. 4.Department of Environmental and Preventive MedicineJichi Medical University School of MedicineTochigiJapan
  5. 5.Laboratory of Environmental Health Sciences, Center for Disease Biology and Integrative Medicine, Graduate School of MedicineThe University of TokyoTokyoJapan

Personalised recommendations